{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:09:21Z","timestamp":1782968961282,"version":"3.54.5"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2034450, 2008956"],"award-info":[{"award-number":["2034450, 2008956"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"DOI":"10.3389\/fendo.2025.1608108","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:10:45Z","timestamp":1748319045000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Approach to prolactin monitoring and hyperprolactinaemia in transgender and gender-diverse individuals undergoing gender affirming hormone therapy"],"prefix":"10.3389","volume":"16","author":[{"given":"Brendan J.","family":"Nolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew I.","family":"Accatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lachlan M.","family":"Angus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada S.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an endocrine society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.v211.3","article-title":"Position statement on the hormonal management of adult transgender and gender diverse individuals","volume":"211","author":"Cheung","year":"2019","journal-title":"Med J Aust"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/trgh.2020.0094","article-title":"The effect of gender-affirming hormones on gender dysphoria, quality of life, and psychological functioning in transgender individuals: A systematic review","volume":"8","author":"van Leerdam","year":"2023","journal-title":"Transgend Health"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41562-023-01605-w","article-title":"A systematic review of psychosocial functioning changes after gender-affirming hormone therapy among transgender people","volume":"7","author":"Doyle","year":"2023","journal-title":"Nat Hum Behav"},{"key":"B6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/15532739.2020.1819505","article-title":"Effects of antiandrogens on prolactin levels among transgender women on estrogen therapy: A systematic review","volume":"21","author":"Wilson","year":"2020","journal-title":"Int J Transgend Health"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1985.tb01081.x","article-title":"Follow-up of prolactin levels in long-term oestrogen-treated male-to-female transsexuals with regard to prolactinoma induction","volume":"22","author":"Gooren","year":"1985","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1988.tb03849.x","article-title":"Prolactin levels and pituitary enlargement in hormone-treated male-to-female transsexuals","volume":"28","author":"Asscheman","year":"1988","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/BF03346388","article-title":"Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients","volume":"31","author":"Vilar","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"B11","first-page":"3","article-title":"Prolactin biology and laboratory measurement: an update on physiology and current analytical issues","volume":"39","author":"Saleem","year":"2018","journal-title":"Clin Biochem Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4065\/80.8.1050","article-title":"Medication-induced hyperprolactinemia","volume":"80","author":"Molitch","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"B14","article-title":"Estrogen replacement therapy increases prolactin levels in postmenopausal women","volume":"4","author":"Fonseca","year":"1997","journal-title":"Menopause"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab427","article-title":"Toward a lowest effective dose of cyproterone acetate in trans women: results from the ENIGI study","volume":"106","author":"Kuijpers","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/and.2017.49.issue-6","article-title":"Prolactin levels during short- and long-term cross-sex hormone treatment: an observational study in transgender persons","volume":"49","author":"Nota","year":"2017","journal-title":"Andrologia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jsm.12571","article-title":"Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence","volume":"11","author":"Wierckx","year":"2014","journal-title":"J Sex Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-47-4-918","article-title":"Progesterone induced acute release of prolactin in estrogen primed ovariectomized women","volume":"47","author":"Rakoff","year":"1978","journal-title":"J Clin Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/lgbt.2016.0190","article-title":"Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment","volume":"4","author":"Defreyne","year":"2017","journal-title":"LGBT Health"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2021.04.008","article-title":"Low-dose cyproterone acetate treatment for transgender women","volume":"18","author":"Even Zohar","year":"2021","journal-title":"J Sex Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae650","article-title":"Effect of spironolactone and cyproterone acetate on breast growth in transgender people: a randomized clinical trial","author":"Angus","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2021.05.003","article-title":"Anti-androgenic effects comparison between cyproterone acetate and spironolactone in transgender women: A randomized controlled trial","volume":"18","author":"Burinkul","year":"2021","journal-title":"J Sex Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/26895269.2024.2323514","article-title":"The efficacy of and user satisfaction with different antiandrogens in Chinese transgender women","volume":"25","author":"Yang","year":"2024","journal-title":"Int J Transgend Health"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsxm.2016.09.012","article-title":"Differential effects of cyproterone acetate vs spironolactone on serum high-density lipoprotein and prolactin concentrations in the hormonal treatment of transgender women","volume":"13","author":"Fung","year":"2016","journal-title":"J Sex Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0101","article-title":"Prolactin levels do not rise among transgender women treated with estradiol and spironolactone","volume":"24","author":"Bisson","year":"2018","journal-title":"Endocr Pract"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/cen.2016.85.issue-2","article-title":"Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: a comparison of safety and effectiveness","volume":"85","author":"Gava","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0370","article-title":"A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen","volume":"183","author":"Gava","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2020-0032","article-title":"Differential endocrine and metabolic effects of testosterone suppressive agents in transgender women","volume":"26","author":"Sofer","year":"2020","journal-title":"Endocr Pract"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvad052","article-title":"Changes in laboratory results in transgender individuals on hormone therapy - a retrospective study and practical approach","author":"Boekhout-Berends","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/jalm\/jfaa028","article-title":"Reproductive endocrinology reference intervals for transgender women on stable hormone therapy","volume":"6","author":"Greene","year":"2021","journal-title":"J Appl Lab Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaf001","article-title":"Laboratory monitoring in transgender and gender-diverse individuals","volume":"71","author":"Nolan","year":"2025","journal-title":"Clin Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy108","article-title":"The occurrence of benign brain tumours in transgender individuals during cross-sex hormone treatment","volume":"141","author":"Nota","year":"2018","journal-title":"Brain"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1111\/cen.2018.89.issue-6","article-title":"Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-A systematic review","volume":"89","author":"McFarlane","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02563-3","article-title":"Hyperprolactinemia and association with prolactinoma in transwomen receiving gender affirming hormone treatment","volume":"72","author":"Raven","year":"2021","journal-title":"Endocrine"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01694-2","article-title":"SIGIS-SIAMS-SIE position statement of gender affirming hormonal treatment in transgender and non-binary people","volume":"45","author":"Fisher","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B36","volume-title":"Guidelines for the Primary and Gender-affirming Care of Transgender and Gender Nonbinary People","author":"Deutsch","year":"2016"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16413","article-title":"Gender-affirming hormone therapy for transgender and gender-diverse adults in Australia","volume":"54","author":"Nolan","year":"2024","journal-title":"Intern Med J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.japh.2023.10.005","article-title":"Patterns of psychotropic medication prescribing and potential drug-hormone interactions among transgender and gender-diverse adults within 2 years of hormone therapy","volume":"64","author":"Kalayjian","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1590\/s2237-96222024v33e2024170.especial.en","article-title":"The use of psychiatric medications and associated factors among people receiving care at a transgender outpatient clinic in Southern Brazil, 2021-2022","volume":"33","author":"Gimenes","year":"2024","journal-title":"Epidemiol Serv Saude"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1608108\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:10:46Z","timestamp":1748319046000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1608108\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":39,"alternative-id":["10.3389\/fendo.2025.1608108"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1608108","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"article-number":"1608108"}}